RNA Biomarker Development


Part 1 – RNA Biomarker Development: Sample to Insight, Dr. Eric Lader
Part 2 – miRNA Profiling in Drug-Induced Liver Injury, Dr. James Dear

Precision medicine offers to transform patient care by targeting treatment to those with most to gain. To date, the most significant advances have been at the level of DNA, for example, the use of somatic DNA alterations as diagnostic indicators of disease and for prediction of pharmacodynamic response. Development of RNA expression signatures as biomarkers has been more problematic. While RNA expression analysis has yielded valuable insights into the biological mechanisms of disease, RNA is a more unstable molecule than DNA, and more easily damaged or degraded during sample collection and isolation. In addition, RNA levels are inherently dynamic and gene expression signatures are extraordinarily complex. Recently, significant progress has been made in identifying key changes in gene expression in cancer and other diseases, as well as identifying expression signatures in circulating nucleic acid that have the potential to be developed into diagnostic and prognostic indicators.

In part 1, Dr. Lader will review strategies for accessing the expression profiles of mRNA, lncRNA and miRNA in both solid tissues and liquid biopsies. Following this overview, in part 2, Dr. Dear will describe the application of human micronome profiling in liquid biopsies to the development of an early minimally invasive biomarker for detection of early stage acetaminophen poisoning in patients.

     
   

Eric Lader

Eric Lader
Dr. Lader has spent over 15 years as a scientist in technology development in the life science market. A molecular biologist by training, Dr. Lader's academic research was in the regulation of gene expression during mammalian development. He received his Ph.D. from Cornell University Medical College in 1989 and did post-doctoral research at the NIH and The University of Texas before moving to biotech. Currently, Dr. Lader is Senior Director of R&D at QIAGEN.
Dr. James Dear

Dr. James Dear

Dr. Dear is Senior Clinical Lecturer in Clinical Pharmacology at the Royal Infirmary of Edinburgh/Edinburgh University and Chief Investigator on the Markers and Paracetamol (Acetaminophen) Poisoning Study (MAPP), a UKCRN portfolio study funded by MRC and co-investigator on the Scottish and Newcastle Antiemetic Pretreatment for Paracetamol Poisoning study.